GLYCYX MOR, INC.
Biotech · Private
Axelopran, a peripherally-restricted opioid antagonist designed to enhance immune checkpoint inhibitor efficacy in cancer patients receiving concurrent opioid analgesia.
- Grants
- $1.2M
- 1 award
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1) | $1,197,275 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1962 | Humanity Inc. | — | $2.4M |
| 1963 | Verastem Oncology | — | — |
| 1964 | VIRONGY BIOSCIENCES, INC. | — | — |
| 1965 | GLYCYX MOR, INC. | — | — |
| 1966 | ARMR Sciences Inc. | — | $30M |
| 1967 | AOBiome LLC | — | $3.7M |
| 1968 | Mersana Therapeutics | — | $69M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods Of Treating Cancer And Other Conditions With A Mu Opioid Receptor Antagonistapplication
- Methods, Systems, And Compositions Related To Use Of Mu Opioid Receptor (mor) Antagonistsapplication
- Methods Of Treating Cancer And Other Conditions With A Mu Opioid Receptor Antagonistapplication
- Methods Of Treating Cancer And Other Conditions With A Mu Opioid Receptor Antagonistapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.